A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

Phase 1

Recruiting

• Conditions: Metastatic Adenocarcinoma of the Pancreas
• Interventions: Drug: BR2021; Drug: BR2021-1

• Registration Number: NCT06867497
• Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Brief Summary

The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas

Detailed Description

Not available

Study Timeline

• Study Start: 2025-02-24
• Study First Submitted: 2025-03-04
• Study First Submitted QC: 2025-03-05
• Study First Posted: 2025-03-10
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-08
• Last Update Posted: 2025-04-10
• Primary Completion: 2025-10-28
• Study Completion: 2025-10-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Those with histologically or cytologically proven metastatic adenocarcinoma of the pancreas
• Those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using medically recognized methods of contraception (contraceptives administration & transplantation or intrauterine device(IUD), sterilization(vasectomy, tubal ligation, etc.), barrier methods (spermicide & male condom, combined use of contraceptive diaphragm, sponge or cervical cap)) from the date of the first administration of the investigational products to at least 6 months after the last administration date and disagree to provide their sperm or ovum.
• Those who spontaneously decide to participate and sign written consent to comply with the subject's precautions after listening to and fully understanding detailed explanation of this clinical trial

Exclusion Criteria

• In the case of a female subject, pregnant woman or those suspected pregnancy or lactating woman.
• Those who have to administer this study's contraindicated drugs with the investigational product from 2 weeks before the participation until end of this study
• Those who can't discontinue a diet (ex. raw grapefruit, grapefruit juice or food containing grapefruit, etc.) that may affect the absorption, distribution, metabolism, and excretion of the drug from 48 hours before the first administration date to post study visit(PSV)
• Those who can't discontinue other drugs except the investigational product of this study that may affect the metabolism and excretion of the drug for the entire study period (However, if necessary, such as treatment of adverse event, it can be administrated according to investigator's judgment)
• Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 4 weeks before the first administration date (However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) or those whose last administration date of their investigational products of other clinical trials doesn't elapse five times the half-life of their investigational products based on the first administration date of investigational product of this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Test drug	BR2021	-
Reference drug	BR2021-1	-

Primary Outcome Measures

Name	Time	Method
AUCt	0~72 hours after administration	Area under the Plasma Concentration-Time Curve from 0 to time t
Cmax	0~72 hours after administration	Maximum Concentration of Drug in Plasma

Trial Locations

Locations (2)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea Seoul St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of